Urosolvine (Methenamine Hippurate) in Renal Impairment: Dosing & Safety

Methenamine hippurate (Urosolvine, Hiprex) is a urinary antiseptic that releases formaldehyde in acidic urine (pH <5.5). It is renally eliminated—dose adjustment and monitoring are essential in kidney disease.

Pharmacokinetics in Renal Impairment

  • Reduced GFR → decreased clearance → accumulation of methenamine and hippuric acid.
  • Accumulation may increase adverse effects (nausea, vomiting, rash, crystalluria, bladder irritation).
  • Efficacy requires acidic urine; renal tubular acidosis or alkali therapy may alkalinize urine, reducing effectiveness.

Dosing Guidelines (General)

  • Normal renal function: 1 g (1 tablet) PO BID.
  • CrCl 30–50 mL/min: Consider 1 g daily; monitor closely.
  • CrCl 10–30 mL/min: Use with caution; 0.5–1 g daily; frequent monitoring.
  • CrCl <10 mL/min / Dialysis: Generally contraindicated; alternative agents preferred.

Monitoring Parameters

  • Renal function (SCr, eGFR) at baseline, 1–2 weeks, then periodically.
  • Urine pH (target <5.5; ascorbic acid 1–2 g/day if needed).
  • Signs of accumulation: worsening GI symptoms, crystalluria (flank pain, hematuria).
  • Clinical response: reduction in recurrent UTI frequency.

Alternatives for Significant Renal Impairment

  • Nitrofurantoin (avoid if CrCl <30 mL/min—pulmonary/neuropathy risk)
  • Fosfomycin (single dose; minimal renal adjustment)
  • Cephalexin, TMP-SMX (dose-adjust)
  • Non-antibiotic: D-mannose, cranberry (PACs), probiotics, vaginal estrogen (postmenopausal)

Always consult nephrology or infectious disease for complex cases. Self-medication is dangerous.

Kidney Disease - Related Articles